Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma

Giuseppe Pelosi, Felice Pasini, Angelica Sonzogni, Fausto Maffini, Patrick Maisonneuve, Antonio Iannucci, Alberto Terzi, Giovanni De Manzoni, Enrica Bresaola, Giuseppe Viale

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Approximately 10-20% of nonsmall cell lung carcinomas (NSCLC) show neuroendocrine (NE) differentiation, as evaluated by panendocrine markers or ultrastructural evidence of dense-core secretory granules. However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC. METHODS. The authors analyzed 220 consecutive patients with Stage I NSCLC (pT1-T2N0M0) among 2100 patients with primary lung carcinoma who underwent surgical treatment between 1987 and 1993. Using light microscopy and immunohistochemical staining for synaptophysin, chromogranin A, and respiratory tract-related hormones, 28 NSCLC specimens with NE differentiation (NSCLC-ND) and 11 large cell neuroendocrine carcinoma (LCNEC) specimens were identified. RESULTS. The 28 NSCLC-ND specimens included 15 adenocarcinomas and 13 squamous cell carcinomas. Neoplastic cells with NE features never exceeded 20% in NSCLC-ND specimens, whereas neoplastic cells amounted to 20-90% in LCNEC specimens. NSCLC-ND specimens with > 5% NE -differentiated tumor cells showed increased Ki-67 labeling index (P = 0.007) and invasive phenotype, as evaluated by fascin immunoreactivity (P = 0.021). Patients with adenocarcinoma, but not with squamous cell carcinoma, who had > 5% NE-differentiated cells had a worse clinical course compared with patients who had ordinary NSCLC, with reduced overall survival (P = 0.017) and disease free survival (P = 0.049). In multivariate analysis, NE differentiation > 5% neoplastic cells in patients with adenocarcinoma independently predicted a poorer prognosis (hazard ratio, 2.61; 95% confidence interval, 0.99-6.85). Hormone production was restricted to chromogranin positive NSCLC-ND but did not affect prognosis. CONCLUSIONS. Stage I adenocarcinomas with ≥ 5% NE tumor cells are clinically aggressive tumors, similar to LCNEC. Hormone production identifies a more fully developed neuroendocrine phenotype but is not relevant to prognosis. The identification of NE- differentiated cells in patients with NSCLC may have clinical relevance.

Original languageEnglish
Pages (from-to)2487-2497
Number of pages11
JournalCancer
Volume97
Issue number10
DOIs
Publication statusPublished - May 15 2003

Fingerprint

Hormones
Carcinoma
Lung
Neuroendocrine Carcinoma
Neuroendocrine Cells
Large Cell Carcinoma
Adenocarcinoma
Neuroendocrine Tumors
Squamous Cell Carcinoma
Chromogranins
Phenotype
Chromogranin A
Synaptophysin
Secretory Vesicles
Respiratory System
Disease-Free Survival
Microscopy
Multivariate Analysis
Confidence Intervals
Staining and Labeling

Keywords

  • Chromogranin A
  • Hormone
  • Immunohistochemistry
  • Neuroendocrine differentiation
  • Nonsmall cell lung carcinoma
  • Survival
  • Synaptophysin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma. / Pelosi, Giuseppe; Pasini, Felice; Sonzogni, Angelica; Maffini, Fausto; Maisonneuve, Patrick; Iannucci, Antonio; Terzi, Alberto; De Manzoni, Giovanni; Bresaola, Enrica; Viale, Giuseppe.

In: Cancer, Vol. 97, No. 10, 15.05.2003, p. 2487-2497.

Research output: Contribution to journalArticle

@article{3edd57e96cff49db91c1dc3a3bfacae7,
title = "Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma",
abstract = "BACKGROUND. Approximately 10-20{\%} of nonsmall cell lung carcinomas (NSCLC) show neuroendocrine (NE) differentiation, as evaluated by panendocrine markers or ultrastructural evidence of dense-core secretory granules. However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC. METHODS. The authors analyzed 220 consecutive patients with Stage I NSCLC (pT1-T2N0M0) among 2100 patients with primary lung carcinoma who underwent surgical treatment between 1987 and 1993. Using light microscopy and immunohistochemical staining for synaptophysin, chromogranin A, and respiratory tract-related hormones, 28 NSCLC specimens with NE differentiation (NSCLC-ND) and 11 large cell neuroendocrine carcinoma (LCNEC) specimens were identified. RESULTS. The 28 NSCLC-ND specimens included 15 adenocarcinomas and 13 squamous cell carcinomas. Neoplastic cells with NE features never exceeded 20{\%} in NSCLC-ND specimens, whereas neoplastic cells amounted to 20-90{\%} in LCNEC specimens. NSCLC-ND specimens with > 5{\%} NE -differentiated tumor cells showed increased Ki-67 labeling index (P = 0.007) and invasive phenotype, as evaluated by fascin immunoreactivity (P = 0.021). Patients with adenocarcinoma, but not with squamous cell carcinoma, who had > 5{\%} NE-differentiated cells had a worse clinical course compared with patients who had ordinary NSCLC, with reduced overall survival (P = 0.017) and disease free survival (P = 0.049). In multivariate analysis, NE differentiation > 5{\%} neoplastic cells in patients with adenocarcinoma independently predicted a poorer prognosis (hazard ratio, 2.61; 95{\%} confidence interval, 0.99-6.85). Hormone production was restricted to chromogranin positive NSCLC-ND but did not affect prognosis. CONCLUSIONS. Stage I adenocarcinomas with ≥ 5{\%} NE tumor cells are clinically aggressive tumors, similar to LCNEC. Hormone production identifies a more fully developed neuroendocrine phenotype but is not relevant to prognosis. The identification of NE- differentiated cells in patients with NSCLC may have clinical relevance.",
keywords = "Chromogranin A, Hormone, Immunohistochemistry, Neuroendocrine differentiation, Nonsmall cell lung carcinoma, Survival, Synaptophysin",
author = "Giuseppe Pelosi and Felice Pasini and Angelica Sonzogni and Fausto Maffini and Patrick Maisonneuve and Antonio Iannucci and Alberto Terzi and {De Manzoni}, Giovanni and Enrica Bresaola and Giuseppe Viale",
year = "2003",
month = "5",
day = "15",
doi = "10.1002/cncr.11376",
language = "English",
volume = "97",
pages = "2487--2497",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma

AU - Pelosi, Giuseppe

AU - Pasini, Felice

AU - Sonzogni, Angelica

AU - Maffini, Fausto

AU - Maisonneuve, Patrick

AU - Iannucci, Antonio

AU - Terzi, Alberto

AU - De Manzoni, Giovanni

AU - Bresaola, Enrica

AU - Viale, Giuseppe

PY - 2003/5/15

Y1 - 2003/5/15

N2 - BACKGROUND. Approximately 10-20% of nonsmall cell lung carcinomas (NSCLC) show neuroendocrine (NE) differentiation, as evaluated by panendocrine markers or ultrastructural evidence of dense-core secretory granules. However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC. METHODS. The authors analyzed 220 consecutive patients with Stage I NSCLC (pT1-T2N0M0) among 2100 patients with primary lung carcinoma who underwent surgical treatment between 1987 and 1993. Using light microscopy and immunohistochemical staining for synaptophysin, chromogranin A, and respiratory tract-related hormones, 28 NSCLC specimens with NE differentiation (NSCLC-ND) and 11 large cell neuroendocrine carcinoma (LCNEC) specimens were identified. RESULTS. The 28 NSCLC-ND specimens included 15 adenocarcinomas and 13 squamous cell carcinomas. Neoplastic cells with NE features never exceeded 20% in NSCLC-ND specimens, whereas neoplastic cells amounted to 20-90% in LCNEC specimens. NSCLC-ND specimens with > 5% NE -differentiated tumor cells showed increased Ki-67 labeling index (P = 0.007) and invasive phenotype, as evaluated by fascin immunoreactivity (P = 0.021). Patients with adenocarcinoma, but not with squamous cell carcinoma, who had > 5% NE-differentiated cells had a worse clinical course compared with patients who had ordinary NSCLC, with reduced overall survival (P = 0.017) and disease free survival (P = 0.049). In multivariate analysis, NE differentiation > 5% neoplastic cells in patients with adenocarcinoma independently predicted a poorer prognosis (hazard ratio, 2.61; 95% confidence interval, 0.99-6.85). Hormone production was restricted to chromogranin positive NSCLC-ND but did not affect prognosis. CONCLUSIONS. Stage I adenocarcinomas with ≥ 5% NE tumor cells are clinically aggressive tumors, similar to LCNEC. Hormone production identifies a more fully developed neuroendocrine phenotype but is not relevant to prognosis. The identification of NE- differentiated cells in patients with NSCLC may have clinical relevance.

AB - BACKGROUND. Approximately 10-20% of nonsmall cell lung carcinomas (NSCLC) show neuroendocrine (NE) differentiation, as evaluated by panendocrine markers or ultrastructural evidence of dense-core secretory granules. However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC. METHODS. The authors analyzed 220 consecutive patients with Stage I NSCLC (pT1-T2N0M0) among 2100 patients with primary lung carcinoma who underwent surgical treatment between 1987 and 1993. Using light microscopy and immunohistochemical staining for synaptophysin, chromogranin A, and respiratory tract-related hormones, 28 NSCLC specimens with NE differentiation (NSCLC-ND) and 11 large cell neuroendocrine carcinoma (LCNEC) specimens were identified. RESULTS. The 28 NSCLC-ND specimens included 15 adenocarcinomas and 13 squamous cell carcinomas. Neoplastic cells with NE features never exceeded 20% in NSCLC-ND specimens, whereas neoplastic cells amounted to 20-90% in LCNEC specimens. NSCLC-ND specimens with > 5% NE -differentiated tumor cells showed increased Ki-67 labeling index (P = 0.007) and invasive phenotype, as evaluated by fascin immunoreactivity (P = 0.021). Patients with adenocarcinoma, but not with squamous cell carcinoma, who had > 5% NE-differentiated cells had a worse clinical course compared with patients who had ordinary NSCLC, with reduced overall survival (P = 0.017) and disease free survival (P = 0.049). In multivariate analysis, NE differentiation > 5% neoplastic cells in patients with adenocarcinoma independently predicted a poorer prognosis (hazard ratio, 2.61; 95% confidence interval, 0.99-6.85). Hormone production was restricted to chromogranin positive NSCLC-ND but did not affect prognosis. CONCLUSIONS. Stage I adenocarcinomas with ≥ 5% NE tumor cells are clinically aggressive tumors, similar to LCNEC. Hormone production identifies a more fully developed neuroendocrine phenotype but is not relevant to prognosis. The identification of NE- differentiated cells in patients with NSCLC may have clinical relevance.

KW - Chromogranin A

KW - Hormone

KW - Immunohistochemistry

KW - Neuroendocrine differentiation

KW - Nonsmall cell lung carcinoma

KW - Survival

KW - Synaptophysin

UR - http://www.scopus.com/inward/record.url?scp=0038370938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038370938&partnerID=8YFLogxK

U2 - 10.1002/cncr.11376

DO - 10.1002/cncr.11376

M3 - Article

C2 - 12733148

AN - SCOPUS:0038370938

VL - 97

SP - 2487

EP - 2497

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -